Previous 10 | Next 10 |
home / stock / biovf / biovf news
Swedish Orphan Biovitrum AB (publ) Q2 2022 Earnings Conference Call July 21, 2021 07:00 ET Company Participants Guido Oelkers - Chief Executive Officer Ravi Rao - Head, Research & Development Henrik Stenqvist - Chief Financial Officer Conference Call Participants Eun Yang - Jefferies Chri...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2021 Q2 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2021 Q2 - Results - Earnings Call Presentation
Swedish Orphan Biovitrum AB (BIOVF): Q2 GAAP EPS of SEK0.90.Revenue of SEK3.21B (+4.6% Y/Y)Press Release For further details see: Swedish Orphan Biovitrum AB reports Q2 results
Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum AB (BIOVF) report positive top-line results from the Phase 3 PRINCE study evaluating the efficacy and safety of Empaveli (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria ((PNH)) who are treatment naïve. At week...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2021 Earnings Conference Call May 4, 2021 7:00 AM ET Company Participants Guido Oelkers - CEO Ravi Rao - Head, R&D Henrik Stenqvist - CFO Conference Call Participants Eun Yang - Jefferies Erik Hultgard - Carnegie Christopher Uhde - SEB Peter S...
Swedish Orphan Biovitrum AB (BIOVF): Q1 GAAP EPS of SEK2.36.Revenue of SEK3.66B (-21.1% Y/Y)Press Release For further details see: Swedish Orphan Biovitrum AB reports Q1 results
Full phase 3 data for Apellis Pharmaceuticals' (APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab).The data was published in The New England Journal of Medicine.Full results from the PEG...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2020 Earnings Conference Call February 18, 2021, 07:00 ET Company Participants Guido Oelkers - CEO & President Ravi Rao - Head, Research & Development & Chief Medical Officer Henrik Stenqvist - CFO Conference Call Participants Christop...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q4 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2020 Q4 - Results - Earnings Call Presentation
The drug portfolio of Alexion Pharmaceuticals (ALXN) is led by C5-inhibitors: Ultomiris (ALXN1210/ravulizumab-cwvz) and Soliris (eculizumab). In the wake of its proposed merger with AstraZeneca (AZN), even clinical-stage biopharmaceutical companies focused on complement-mediated therapies hav...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clin...
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a pot...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...